Topcon 3D OCT-1 Maestro Reference Database Study II

Sponsor
Topcon Medical Systems, Inc. (Industry)
Overall Status
Completed
CT.gov ID
NCT02447120
Collaborator
(none)
504
7
5
72
14.3

Study Details

Study Description

Brief Summary

The objective of this study is to collect OCT measurement data on normal healthy eyes in order to determine the reference limits for Topcon 3D OCT-1 Maestro based on the percentile points for 1%, 5%, 95%, and 99%.

Condition or Disease Intervention/Treatment Phase
  • Device: 3D OCT-1 Maestro

Detailed Description

The objective of this study is to collect OCT measurement data on normal healthy eyes in order to determine the reference limits for Topcon 3D OCT-1 Maestro based on the percentile points for 1%, 5%, 95%, and 99%.

Study Design

Study Type:
Observational
Actual Enrollment :
504 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Topcon 3D OCT-1 Maestro Reference Database Study II
Study Start Date :
May 1, 2015
Actual Primary Completion Date :
Oct 1, 2015
Actual Study Completion Date :
Oct 1, 2015

Arms and Interventions

Arm Intervention/Treatment
Normal Eyes

Subjects with no known ocular diseases will be scanned with the Maestro device

Device: 3D OCT-1 Maestro
OCT machines used for diagnostic purposes

Outcome Measures

Primary Outcome Measures

  1. Retinal Thickness [1 minute]

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes

Inclusion Criteria for Normal Group

  1. Subjects 18 years of age or older on the date of informed consent

  2. Subjects able to understand the written informed consent and willing to participate as evidenced by signing the informed consent

  3. Subjects presenting at the site with normal eyes (eyes without pathology)

  4. lOP <= 21 mmHg bilaterally

  5. BCVA 20/40 or better (each eye)

  6. Both eyes must be free of eye disease

Exclusion Criteria for Normal Group

  1. Subjects previously enrolled in either the Maestro AP study or the Maestro2 study

  2. Subjects unable to tolerate ophthalmic imaging

  3. Subject with ocular media not sufficiently clear to obtain acceptable OCT images

  4. HFA visual field (24-2 Sita Standard, white on white) result unreliable (based on manufacturer's recommendation), defined as fixation losses > 20% or false positives> 33%, or false negatives> 33%

  5. Visual field defects consistent with glaucomatous optic nerve damage based on with at least one of the following two findings:

  • On pattern deviation (PD), there exists a cluster of 3 or more points in an expected location of the visual field depressed below the 5% level, at least 1 of which is depressed below the 1% level;

  • Glaucoma hemi-field test "outside normal limits."

  1. Presence of any ocular pathology except for cataract

  2. Narrow angle

  3. History of leukemia, dementia or multiple sclerosis

  4. Concomitant use of hydroxychloroquine and chloroquine

Contacts and Locations

Locations

Site City State Country Postal Code
1 UAB School of Optometry Birmingham Alabama United States 35233
2 Southern California College of Optometry Fullerton California United States 92831
3 Valley Eyecare Center Livermore California United States 94550
4 Western University of Health Sciences Pomona California United States 91716
5 Illinois College of Optometry Chicago Illinois United States 60616
6 New York VA Jamaica New York United States 11425
7 SUNY College of Optometry New York New York United States 10036

Sponsors and Collaborators

  • Topcon Medical Systems, Inc.

Investigators

  • Study Chair: Charles Reisman, MS, Topcon Corporation

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Topcon Medical Systems, Inc.
ClinicalTrials.gov Identifier:
NCT02447120
Other Study ID Numbers:
  • Maestro_NDB_II
First Posted:
May 18, 2015
Last Update Posted:
Jun 8, 2022
Last Verified:
Jun 1, 2022
Keywords provided by Topcon Medical Systems, Inc.

Study Results

No Results Posted as of Jun 8, 2022